TEL AVIV, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Revium Rx (formerly Revium Recovery Inc. (OTC: RVRC), a biopharmaceutical company developing advanced lipid-based therapeutics for infectious and oncologic diseases, today announced significant progress in its regulatory and manufacturing programs supporting the planned Phase 1 clinical trial of its lead product candidate, Nano-Mupirocin - a novel systemic formulation of the well-known and highly potent antibiotic mupirocin.

“Our novel formulation of Nano-Mupirocin is designed to overcome the inherent limitation of mupirocin’s instability in blood and to expand its use beyond topical applications into systemic treatment for severe bacterial infections”, says Amir Avraham, the CEO, - “the formulation aims to maintain therapeutic concentrations in the bloodstream and effectively target deep-tissue infections caused by multidrug-resistant pathogens such as Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Ceftriaxone-Resistant Neisseria gonorrhoeae”.

Last month, the company submitted its clinical trial application to the Israeli Ministry of Health, marking a critical milestone toward the initiation of first-in-human studies in early 2026. Concurrently, Revium Rx, in collaboration with WuXi AppTec, one of the world’s leading global CDMOs, continues to advance the scale-up and production of its GMP clinical batch, with final release expected by the end of 2025.

Addressing the Urgent Threat of Antimicrobial Resistance (AMR)

In 2021, Methicillin-Resistant Staphylococcus Aureus (MRSA) was estimated to have caused approximately 130,000 deaths directly attributable to antimicrobial resistance (AMR) — a sharp rise from 57,200 in 1990. According to the Global Research on Antimicrobial Resistance (GRAM) Project published in The Lancet in 2022, MRSA was responsible for over 100,000 AMR-attributable deaths in 2019, making it one of the deadliest pathogens that year. Broader GRAM data indicate that bacterial AMR was directly responsible for 1.27 million deaths globally in 2019. The United Nations Environment Programme (UNEP) Summit on AMR held in 2024 further underscored the escalating threat, warning that AMR-related fatalities may approach 2 million annually by 2050 without decisive global intervention. The GRAM study projects that without intervention, AMR will directly cause 39 million deaths between 2025 and 2050, with annual mortality expected to rise nearly 70 % by mid-century.

MRSA alone accounts for over 100,000 AMR-attributable deaths annually. These alarming data underscore the urgent medical need for new systemic antibiotics such as Nano-Mupirocin.

Significant and Growing Market Opportunity

The global AMR therapeutics market was valued at USD 8.7 billion in 2023 and is projected to exceed USD 12.5 billion by 2030, growing at a CAGR of 5.3 %, according to Grand View Research, 2024.

Within this rapidly expanding global market, Nano-Mupirocin targets several high-value infectious disease indications, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Ceftriaxone-Resistant Gonorrhea (CR-Gonorrhea). If Nano-Mupirocin demonstrates favorable results in clinical trials, of which no assurance can be provided, the Company will seek to capture a meaningful share within this rapidly expanding market, reflecting both the urgent clinical need and the significant commercial potential of novel antibiotics effective against resistant pathogens. “By targeting these difficult-to-treat infections with a novel nano-liposomal formulation of a known highly-potent antibiotic, ReviumRx is positioned to play a meaningful role in the global fight against AMR”, adds Amir Avraham, the CEO of Revium Rx.

About ReviumRx

Revium Rx (OTC: RVRC) is a preclinical-stage biotechnology company advancing lipid-based and nanoparticle-formulated therapeutics for high-need indications including antimicrobial resistance and solid tumors. The Company focuses on creating smarter, more targeted treatments that improve how medicines work in the body, with the goal of increasing effectiveness while reducing side effects.

For more information, please visit www.reviumrx.com.

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business plan and product development plans, including preclinical and clinical studies; the inherent uncertainties associated with developing new pharma products and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; regulatory delays, manufacturing challenges, and changes in market dynamics and competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.  The Company does not undertake any obligation to publicly update any forward looking statement. Revium Rx is not  subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended.

Company Contact:
Inna Martin
1-800-5191687

Revium Rx (RVRC) Completes Acquisition of LipoVation Ltd.

/EIN News/ -- Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- February 4, 2025 – Revium Rx (formerly Revium Recovery Inc., OTC: RVRC) has completed the strategic acquisition of LipoVation Ltd., an Israeli development-stage company specializing in lipid-based nano/micro particle medicines. This acquisition marks a significant shift in Revium Rx’s focus toward nanoparticle-based therapeutics, positioning the company at the forefront of advanced drug delivery technologies for hard-to-treat diseases.

LipoVation’s core technology was conceptualized by Prof. Yehezkel Barenholz, a world-renowned scientist and the inventor of Doxil, the first FDA-approved liposomal chemotherapy drug, widely used in the treatment of ovarian cancer, multiple myeloma, and AIDS-related Kaposi’s sarcoma. With this acquisition, LipoVation becomes a wholly owned subsidiary of Revium Rx, aligning with the company’s renewed commitment to drug delivery innovation.

Pipeline & Technology Focus

Revium Rx is developing a portfolio of advanced therapeutics, currently in the development stage, aimed at expanding the potential of existing treatments. Key programs include:

• A novel systemic formulation of a highly potent antibiotic, previously limited to topical use, designed to combat antibiotic-resistant bacterial infections.

• A cutting-edge adjuvant to enhance immune checkpoint inhibitors, improving the efficacy of cancer immunotherapies.

• An innovative approach to immunization, leveraging novel peptides and lipid-based technology for emerging infectious diseases.

These next-generation encapsulated therapeutics are built on three core proprietary technologies:

• Clinically validated nanoparticles for targeted drug delivery.

• Advanced drug-loading and release systems to optimize bioavailability.

• Specialized lipid-based carriers for enhanced stability and controlled release.

Leadership & Strategic Direction

Following the acquisition, David Akunis has been appointed as Chief Executive Officer (CEO) of Revium Rx, bringing extensive managerial experience and financial expertise to drive the company’s new direction. With a strong background in fundraising and leadership, he is dedicated to advancing Revium Rx’s mission of developing innovative nanoparticle-based therapeutics and expanding the company’s impact in the pharmaceutical industry.

Inna Martin, who has served as CEO since December 2020, has transitioned to Chief Operating Officer (COO) and President, focusing on product development and clinical trial preparation. This strategic shift ensures that Revium Rx progresses rapidly toward clinical-stage development while expanding strategic partnerships and accelerating growth.

“As the demand for safer and more effective treatments continues to grow, our mission is to expand and enhance the therapeutic potential of existing treatments by utilizing proven drug delivery technologies to improve efficacy, safety, and clinical outcomes,” said David Akunis, CEO of Revium Rx. “Revium Rx's encapsulated therapeutics platform represents a transformative step forward in the fight against resistant infections, cancer, and emerging infectious diseases.”

With this new strategic direction, Revium Rx continues to expand its research and development efforts, forging key partnerships and advancing its pipeline of highly potent therapeutics.

For more information, visit www.reviumrx.com or contact:

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business plan and product development plans; the inherent uncertainties associated with developing new products and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.  The Company does not undertake any obligation to publicly update any forward looking statement. Neither Revium Rx nor LipoVation are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended.

Company Contact:
Inna Martin
1-800-5191687